Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

215results about "Carrier-antigen complex architecture" patented technology

Universal vaccine platform

The disclosure relates to vaccination compositions, for example, against human papillomavirus, Zika virus, and flu virus. The disclosure also relates to vectors for producing the virus-like particles and immune complex platforms of the vaccination compositions.
Owner:THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA

Lamp constructs comprising cancer antigens

The present invention provides improved LAMP Constructs comprising specific fragments of the LAMP lumenal domain to deliver cancer antigens to immune cells for enhanced processing. These LAMP Constructs can be used for the treatment of disease and in particular hyperproliferative disorders and / or cancer. The improved LAMP Constructs allow for presentation of properly configured three dimensional epitopes for production of an immune response when administered to a subject. The improved LAMP Constructs can be multivalent molecules, and / or can be provided as part of a multivalent vaccine containing two or more LAMP Constructs. The improved LAMP Constructs as described herein can also be used to generate antibodies when administered to a non-human vertebrate.
Owner:IMMUNOMIC THERAPEUTICS INC

Intracellular delivery of biomolecules to induce tolerance

The present invention provides methods for inducing tolerance and / or suppressing an immune response to an antigen by passing a cell suspension containing an anucleate cell through a constriction, wherein the constriction deforms the cell thereby causing a perturbation of the cell such that an antigen and / or tolerogenic factor enters the cell. In some embodiments, the anucleate cell is delivered to an individual and the antigen is delivered to and processed in a tolerogenic environment to induce tolerance and / or suppress an immune response to the antigen.
Owner:STEMCELL TECHNOLOGIES CANADA INC

Peptide immunogens targeting islet amyloid polypeptide (IAPP) and formulations thereof for prevention and treatment of disorders related to aggregated iapp

The present disclosure is directed to peptide immunogen constructs targeting portions of Islet Amyloid Polypeptide (IAPP), compositions containing the constructs, antibodies elicited by the constructs, and methods for making and using the constructs and compositions thereof. The disclosed peptide immunogen constructs have more than about 30 amino acids and contain (a) a B cell epitope having about more than about 6 contiguous amino acid residues from the IAPP aggregation prone region of the full-length IAPP protein; (b) a heterologous Th epitope; and (c) an optional heterologous spacer. The disclosed IAPP peptide immunogen constructs stimulate the generation of highly specific antibodies directed IAPP for the prevention and / or treatment of disorders associated with aggregated IAPP.
Owner:VAXXINITY INC

Chimeric antigen receptors targeting tumor microenvironment

To provide methods and compositions for use in treating cancer, which may be achieved by targeting of a tumor microenvironment.SOLUTION: The invention provides an immune cell engineered to express: (a) a chimeric antigen receptor (CAR) polypeptide including an extracellular domain including a first antigen-binding domain that binds to a first antigen and a second antigen-binding domain that binds to a second antigen; and (b) a bispecific T cell engager (BiTE), wherein the BiTE binds to a target antigen and a T cell antigen.SELECTED DRAWING: Figure 1
Owner:THE GENERAL HOSPITAL CORP

Compositions of nucleic acid nanostructures for vaccines and methods of use thereof

Compositions containing a nucleic acid nanostructure having a desired geometric shape and an antigen and / or immunostimulatory agent(s) bound to its surface are provided. The nanostructure design allows for control of the relative position and / or stoichiometry of the immunostimulatory agent(s) bound to its surface. The antigen and / or immunostimulatory agent(s) displayed on the nanostructure surface are arranged with the preferred number, spacing, and 3D organization to elicit a robust immune response. The displayed antigen can be eOD-GT8. The immunostimulatory agent can be, e.g., T cell epitope such as a pan HLA DR-binding epitope (PADRE) and / or a lectin such as MBL or C3, or ligand thereof such as a glycan including mannose. Also provided are antigen-T cell epitope fusions such as eOD-PADRE and nanostructures presenting the same. The immunostimulatory compositions may thus be useful as immunogens, vaccines, adjuvants, and the like. Methods of inducing immune responses are also provided.
Owner:MASSACHUSETTS INST OF TECH

RSV vaccine composition, method and use thereof

An immunogenic composition comprising a recombinant peptide and a protein, wherein the recombinant peptide and the protein comprise a respiratory syncytial virus (RSV) viral antigen and an immunogen such as an RSV F protein peptide. The immunogenic composition comprises a secreted fusion protein, the secreted fusion protein comprises a soluble RSV virus antigen, and the soluble RSV virus antigen is linked with the C-terminal part of collagen by means of in-frame fusion to form a disulfide bond-linked trimer fusion protein. The immunogenic composition can be used for producing an immune response, for example for treating or preventing RSV infection. The immunogenic composition can be used in a vaccine composition, for example as part of a prophylactic and / or therapeutic vaccine. Further provided are a method for producing the recombinant peptide and protein, prevention, treatment and / or diagnosis methods and related kits.
Owner:SICHUAN CLOVER BIOPHARM INC

Compositions and methods for stabilization of active agents

Provided herein are methods and compositions for stabilization of active agents. The active agents are distributed, mixed or embedded in a silk fibroin matrix, thereby retaining the bioactivity of the active agents upon storage and / or transportation. In some embodiments, the storage-stable vaccine-silk compositions are also provided herein.
Owner:TRUSTEES OF TUFTS COLLEGE

Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen

The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of infectious diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.
Owner:CUREVAC SE

Vaccine composition comprising m2e nanoparticles and ha1 protein

The present invenon relates to a vaccine against influenza A viruses, said vaccine comprising HA protein and nanostructures bearing M2e, and its use for vaccinaon against avian influenza, especially in the veterinary field.
Owner:INST NAT DE RECH POUR LAGRICULTURE +3

T-Cell Modulatory Multimeric Polypeptide with Conjugation Sites and Methods of Use Thereof

InactiveUS20240409606A1Antibody mimetics/scaffoldsPeptide/protein ingredientsEpitopeImmunomodulatory peptide
The present disclosure provides T-cell modulatory multimeric polypeptides (“T-Cell-MMPs”) comprising an immunomodulatory polypeptide (“MOD”) that may be selected to exhibit reduced binding affinity to a cognate co-immunomodulatory polypeptide (“Co-MOD”) and a location for covalently attaching a molecule that can serve as an epitope, such as an epitope peptide. Once the epitope molecule is attached the resulting T-Cell-MMP-epitope conjugates are useful for modulating the activity of a T-cell by delivering immunomodulatory peptides, such as IL-2 or IL-2 variants that exhibit reduced binding affinity for IL-2R, to the T-cells in an epitope selective / specific manner, and accordingly, for modulating an immune response in an individual.
Owner:CUE BIOPHARMA INC

Intracellular delivery of biomolecules to induce tolerance

The present invention provides methods for inducing tolerance and / or suppressing an immune response to an antigen by passing a cell suspension containing an anucleate cell through a constriction, wherein the constriction deforms the cell thereby causing a perturbation of the cell such that an antigen and / or tolerogenic factor enters the cell. In some embodiments, the anucleate cell is delivered to an individual and the antigen is delivered to and processed in a tolerogenic environment to induce tolerance and / or suppress an immune response to the antigen.
Owner:STEMCELL TECHNOLOGIES CANADA INC

Stabilized coronavirus spike (s) protein immunogens and related vaccines

The present invention provides redesigned soluble coronavirus S protein derived immunogens that are stabilized via specific modifications in the wildtype soluble S sequences. Also provided in the invention are nanoparticle vaccines that contain the redesigned soluble S immunogens displayed on self-assembling nanoparticles. Polynucleotide sequences encoding the redesigned immunogens and the nanoparticle vaccines are also provided in the invention. The invention further provides methods of using the vaccine compositions in various therapeutic applications, e.g., for preventing or treating coronaviral infections.
Owner:THE SCRIPPS RES INST

Norovirus S particle based vaccines and methods of making and using same

Disclosed herein are vaccine compositions, in particular, polyvalent icosahedral compositions for antigen presentation. The disclosed compositions may contain an S particle made up of recombinant fusion proteins. The recombinant fusion proteins may include a norovirus (NoV) S domain protein, a linker protein domain operatively connected to the norovirus S domain protein, and an antigen protein domain operatively connected to said linker.
Owner:CHILDRENS HOSPITAL MEDICAL CENT CINCINNATI

Heterologous Prime Boost Vaccine

The present invention pertains to the provision of a vaccine comprising a first component (K) and a second component (V), wherein the first component (K) comprises a complex in which a cell penetrating peptide, an antigenic domain and a TLR agonist are functionally linked and the second component (V) comprises an oncolytic recombinant vesicular stomatitis virus expressing an antigenic domain. The invention further pertains to the use of the inventive vaccine in the treatment of cancer. The invention also provides a recombinant vesicular stomatitis virus expressing an antigenic domain and its use in cancer vaccines.
Owner:BOEHRINGER INGELHEIM INT GMBH

Highly stable antigen-presenting fusion proteins and uses thereof as vaccine components for the therapy and / or prophylaxis of pathogenic bacteria

The present invention relates to antigens, more particularly protein antigens of enterococcal pathogens derived from the protein AdcA that are particularly useful as vaccine components and constructs for therapy and / or prophylaxis of bacterial infections. The present invention further relates to antibodies directed against the antigens of the invention and medical uses thereof.
Owner:LMU KLINIKUM ANSTALT DES ÖFFENTLICHEN RECHTS DES FREISTAATES BAYERN - KINDERKLINIK & KINDERPOLIKLINIK IM DR VON HAUNERSCHEN KINDERSPITAL +1

Peptide based vaccines for inducing immune response and production methods and uses thereof for inducing immune response

To provide peptide-based vaccines for inducing immune response and production methods and uses thereof.SOLUTION: The present disclosure relates to novel peptide-based vaccines, methods of manufacturing the novel peptide-based vaccines and uses thereof for delivering peptide antigens to induce an immune response, and in particular a T cell response to a subject. The present inventors have developed novel compositions and methods of manufacturing peptide-based vaccines that overcome at least one of the limitations of current peptide-based vaccine approaches. The novel peptide-based vaccine compositions and methods of manufacturing disclosed herein account for the variability in the physical and chemical properties of peptide antigens and are therefore generalizable for any peptide antigen.SELECTED DRAWING: None
Owner:BARINTHUS BIOTHERAPEUTICS NORTH AMERICA INC +1

Protein-based nanoparticle vaccine for metapneumovirus

Provided are virus-like particle vaccines for human metapneumovirus (hMPV) in which the ectodomain of hMPV F protein is linked to, and thereby displayed on, a symmetric protein-based virus-like particle. For example, the vaccine antigen may be a N-terminal fusion of the ectodomain of hMPV F protein to a protein having a multimerization domain for a one- or two-component virus-like particle, such as a two-component icosahedral virus-like particle. Further provided are vaccine compositions, methods of manufacturing, and methods of use, e.g., immunizing a subject to generate a protective immune response to hMPV.
Owner:ICOSAVAX INC

Peptide-based vaccines for inducing immune responses, methods for their production and use - Patents.com

To provide peptide-based vaccines for inducing immune response and production methods and uses thereof.SOLUTION: The present disclosure relates to novel peptide-based vaccines, methods of manufacturing the novel peptide-based vaccines and uses thereof for delivering peptide antigens to induce an immune response, and in particular a T cell response to a subject. The present inventors have developed novel compositions and methods of manufacturing peptide-based vaccines that overcome at least one of the limitations of current peptide-based vaccine approaches. The novel peptide-based vaccine compositions and methods of manufacturing disclosed herein account for the variability in the physical and chemical properties of peptide antigens and are therefore generalizable for any peptide antigen.SELECTED DRAWING: None
Owner:BARINTHUS BIOTHERAPEUTICS NORTH AMERICA INC +1

Malaria protein nanoparticle vaccines and uses thereof

The invention provides a composition comprising a Plasmodium species multimeric protein capable of forming a nanoparticle and at least one antigen of interest, wherein the multimeric protein comprises a monomer chosen from Plasmodium species pyridoxal 5'-phosphate synthase (PLP), chaperone 60 protein (Cpn60), and caseinolytic protease (Clp). In embodiments, the invention provides the composition wherein the monomers assemble to form a multimeric nanoparticle and / or which comprises an adjuvant. The invention further provides a nucleic acid encoding the multimeric protein and the at least one antigen of interest, E. coli comprising the nucleic acid, and the use of such in a method for producing the inventive multimeric protein and the at least one antigen of interest. Also provided are a method and use of the inventive multimeric protein and the at least one antigen of interest for immunizing a subject against Plasmodium species.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES +4

Modified h5 influenza hemagglutinin polypeptides and nucleic acids and uses thereof

This application relates to modified H5 influenza hemagglutinin polypeptides and messenger ribonucleic acids (mRNAs) encoding the same, as well as compositions and vaccines comprising the same and methods of using the same, such as in the prevention and / or treatment of diseases or conditions caused by influenza A viruses, particularly influenza A virus, subtype H5, such as H5N8 or H5N1.
Owner:SANOFI SA(FR)

Methods and compositions for treating hepatitis b infection

The invention relates to methods and compositions for treating hepatitis B infection. Disclosed is a biological nanoparticle (BNP) comprising a hepatophilic DNA virus envelope HBsAg-S fusion protein comprising one or more epitope regions wherein the epitope regions are selected from the group consisting of epitopes expressed in the Ring 1 region and the Ring 2 region of the HBsAg-S domain, and wherein the epitope regions comprise one or more of CTKPTDGNC (SEQ ID NO: 34) and / or CKTCTTPAQGNSMFPS (SEQ ID NO: 35).
Owner:MELBOURNE HEALTH

Mechanically interlocking complexes

Provided herein are functionalized monoclonal antibodies (mAbs) including antibody fragments, including those where a Fab-binding molecule (Fab binding moiety) linked to a steric hindering molecule (steric hindering chemical moiety) is mechanically interlocked (e.g., through noncovalent conjugation) with the antibody or antibody fragment. Also provided are compositions that form highly stable and versatile drug delivery and diagnostic compositions.
Owner:CITY OF HOPE

Antigenic multimeric respiratory syncytial virus polypeptides

To provide antigenic multimeric respiratory syncytial virus (RSV) G polypeptides for use in eliciting an immune response to RSV.SOLUTION: Provided is an antigenic RSV G polypeptide comprising more than two RSV Gcc monomers, where the polypeptide does not comprise ferritin. Also provided is a method of eliciting an immune response to RSV or protecting a subject against RSV infection, comprising the step for administering the antigenic RSV G polypeptide or composition to a subject.SELECTED DRAWING: None
Owner:SANOFI SA(FR)

Lipid nanocarrier vaccine

The present disclosure relates to a lipid nanoparticle which is a carrier for an antigen. The present disclosure also relates to an immunogenic composition comprising the antigen. The immunogenic composition may be a vaccine composition. The present disclosure further relates to methods and uses of the carrier and immunogenic composition.
Owner:ROYAL MELBOURNE INST OF TECH

Phagocytic particles for treating or preventing cancer

The present invention provides phagocytic particles for treating or preventing cancer in a subject, wherein the phagocytic particle comprises a core and a neoantigen construct tightly associated with the core, and wherein the neoantigen construct comprises a neoepitope peptide having an amino acid sequence corresponding to the amino acid sequence of a portion of a protein or peptide known or suspected to be expressed by a cancer cell in the subject, wherein the portion of the protein or peptide has at least one somatically mutated amino acid. The present invention also relates to an injectable pharmaceutical composition for treating or preventing cancer.
Owner:NEOGAP THERAPEUTICS AB

Compositions and methods for the treatment of myeloproliferative neoplasms

PCT designated stageWO2025207632A1ChemokinesAntibody mimetics/scaffoldsPharmacy medicineCalreticulin
Nucleic acids encoding recombinant fusion proteins directed to calreticulin are described, as well as pharmaceutical compositions comprising such nucleic acids and therapeutic methods using such nucleic acids and pharmaceutical compositions, such as for treating cancer.
Owner:REGENERON PHARMACEUTICALS INC

Pentameric toxin protein-based target protein fusion pentamer production platform using viral nucleocapsids

ActiveJP2025522293AFungiBacteria
The expression vector for producing the target protein-fused pentamer of the present invention contains polynucleotides encoding a pentameric toxin protein and a viral nucleocapsid as fusion partners of the target protein. Further, the method for producing the target protein-fused pentamer of the present invention includes the steps of: producing an expression vector for producing the target protein-fused pentamer, which contains a target protein and polynucleotides encoding a pentameric toxin protein and a viral nucleocapsid as fusion partners of the target protein; introducing the expression vector for producing the target protein-fused pentamer into a host cell to produce a transformant; and culturing the transformant.
Owner:バクスディグム カンパニーリミティド +1